DafinchiKey Factors Behind Q4 Operating Margin Decline at Haemonetics 2026
This discussion explores the key factors that impacted Haemonetics' Q4 operating margins in 2026, including tariffs, claims expenses, and strategic investments.
Read post
Detailed company information
Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
Last Updated: Sep 2026
Earnings Transcript for 2027 - Q1Released: Aug 06, 2026
Earnings Transcript for 2026 - Q4Released: May 08, 2026
Earnings Transcript for 2026 - Q3Released: Feb 05, 2026
Earnings Transcript for 2026 - Q2Released: Nov 07, 2025
Earnings Transcript for 2026 - Q1Released: Aug 09, 2025
Earnings Transcript for 2025 - Q4Released: May 10, 2025
Earnings Transcript for 2025 - Q3Released: Feb 06, 2025
Earnings Transcript for 2025 - Q2Released: Nov 09, 2024
Earnings Transcript for 2025 - Q1Released: Aug 08, 2024
Earnings Transcript for 2024 - Q4Released: May 10, 2024
Earnings Transcript for 2024 - Q3Released: Feb 08, 2024
Earnings Transcript for 2024 - Q2Released: Nov 03, 2023
Earnings Transcript for 2024 - Q1Released: Aug 08, 2023
Earnings Transcript for 2023 - Q4Released: May 11, 2023
Earnings Transcript for 2023 - Q3Released: Feb 07, 2023
Earnings Transcript for 2023 - Q2Released: Nov 07, 2022
Earnings Transcript for 2023 - Q1Released: Aug 10, 2022
Earnings Transcript for 2022 - Q4Released: May 10, 2022
Earnings Transcript for 2022 - Q3Released: Feb 08, 2022
Earnings Transcript for 2022 - Q2Released: Nov 09, 2021
Earnings Transcript for 2022 - Q1Released: Aug 11, 2021
Earnings Transcript for 2021 - Q4Released: May 13, 2021
Earnings Transcript for 2021 - Q3Released: Feb 02, 2021
Earnings Transcript for 2021 - Q2Released: Nov 04, 2020
ANGO AngioDynamics, Inc.
ATRC AtriCure, Inc.
ICUI ICU Medical, Inc.
MMSI Merit Medical Systems, Inc.
NVST Envista Holdings Corp
ATR AptarGroup, Inc.
TFX Teleflex Incorporated
COO The Cooper Companies, Inc.
WST West Pharmaceutical Services, Inc.
RMD ResMed Inc.
HALO Halozyme Therapeutics, Inc.
TMO Thermo Fisher Scientific Inc.
This discussion explores the key factors that impacted Haemonetics' Q4 operating margins in 2026, including tariffs, claims expenses, and strategic investments.
Read post